

September 1, 2016



# **Abeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference**

## **Company COO to Present on Thursday, September 8th at 9:30 am ET**

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 09/01/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene and plasma-based therapies for life-threatening rare genetic diseases, today announced that COO, Jeffrey Davis will be presenting for the company at Landmark Angels 6<sup>th</sup> Annual Investing for Cures 2016 Conference in New York City, September 8, 2016 at 9:30 am ET.

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: at Landmark Angels 6<sup>th</sup> annual Investing for Cures 2016 Conference

Date: Thursday, September 8<sup>th</sup>, 2016

Time: 9:30 am ET

Location: Club 101 in New York City, NY

### ***Abeona Recent Highlights:***

- August 29, 2016, Abeona completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients
- August 9, 2016, Abeona announced a collaboration with the EB Research Partnership, EB Medical Research Foundation and Stanford University for the development of treatments for recessive dystrophic epidermolysis bullosa (RDEB). Clinical results for the lead EB program (EB-101) were recently presented at the opening Plenary Session of the Society for Investigative Dermatology in May 2016, and Investigators at Stanford are recruiting patients for a Phase 2 clinical trial of EB-101 in adolescents age 13 and older to determine the effect of type VII collagen gene corrective grafts on wound healing efficacy.
- August 4, 2016, Abeona announced it had received European regulatory approval by the Agencia Espanola de Medicamentos y Productos Sanitarios for its Phase 1/2 trial for ABO-102 (AAV-SGSH) to be conducted at Cruces University Hospital (Bilbao, Spain)
- August 2, 2016, Abeona provided an update on the initial subjects enrolled in this trial, stating that ABO-102 had been well tolerated with no safety or tolerability concerns identified through 30-days post-injection, and that encouraging signs of early biopotency had been observed in urinary and CSF GAG (heparan sulfate) measurements as well as potential disease-modifying effects in the liver and spleen.

- May 24, 2016, Abeona announced the FDA Allowance of its Investigational New Drug (IND) for a Phase 1/2 clinical study with ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B (MPS IIIB)
- May 17, 2016, Abeona announced that the first patient in its Phase 1/2 trial for ABO-102 (AAV-SGSH), a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A (MPS IIIA), has been enrolled at Nationwide Children's Hospital in Columbus, Ohio

**About Abeona :** Abeona Therapeutics Inc. is a clinical stage company developing gene and plasma-based therapies for life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha<sup>™</sup> (alpha-1 protease inhibitor) for inherited COPD, utilizing its proprietary SDF<sup>™</sup> (Salt Diafiltration) ethanol-free process. For more information, visit [www.abeonatherapeutics.com](http://www.abeonatherapeutics.com).

*This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that we are looking forward to advancing multiple important new therapeutic candidates for the treatment of epidermolysis bullosa, that we plan to accelerate up to three new promising EB product candidates toward commercialization, that encouraging signs of early biopotency had been observed in urinary and CSF GAG (heparan sulfate) measurements as well as potential disease-modifying effects in the liver and spleen in our ABO-102 program, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.*

Company and Media Contact:

Andre'a Lucca

Vice President, Communications & Operations

Abeona Therapeutics Inc

+1 (212)-786-6208

[alucca@abeonatherapeutics.com](mailto:alucca@abeonatherapeutics.com)

Christine Berni-Silverstein

Vice President, Investor Relations  
Abeona Therapeutics Inc  
+1 (212)-786-6212  
[csilverstein@abeonatherapeutics.com](mailto:csilverstein@abeonatherapeutics.com)

Source: Abeona Therapeutics